ClinicalTrials.gg
CompletedNCT02557139Updated May 25, 2022Results posted

Bioavailability of Belumosudil (KD025) in Healthy Male Subjects

A Phase 1 interventional study of Belumosudil Tablet and Belumosudil Capsule in Bioavailability, sponsored by Kadmon Corporation, LLC. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-25.

Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

Phase 1 bioavailability study to evaluate the pharmacokinetics (PK) and tolerability/safety of the belumosudil tablet formulation in the fasted and fed states and compared to the belumosudil capsule formulation in the fed state.

Read the detailed description

This is a Phase 1, 3-way, crossover, randomized, open-label study in healthy subjects designed to compare the bioavailability of belumosudil (previously known as KD025) tablet formulation administered in the fed and fasted states and to assess the relative bioavailability of belumosudil tablet and capsule formulations in the fed state.

The primary objective of the study is to determine the PK parameters of belumosudil tablet formulation in the fed and fasted states.

The secondary objectives of the study are: (1) to assess the relative bioavailability of a tablet (test) to capsule (reference formulation of belumosudil; (2) to assess and compare the variability in the maximum concentration (Cmax) and area under the concentration-time curve (AUC) for belumosudil treatments (belumosudil 200 mg tablet in the fasting state, belumosudil 200 mg tablet in the fed state, and belumosudil as two 100 mg capsules in the fed state); and (3) to provide additional safety and tolerability information for belumosudil.

This is a single-center, open-label, randomized, single-dose, 3-period, 3-way, crossover study in healthy subjects.

In each of 3 study periods, each subject receives 1 of the following single-dose treatments:

  • Regimen A: Belumosudil 200 mg tablet in the fasted state
  • Regimen B: Belumosudil 200 mg tablet in the fed state
  • Regimen C: Belumosudil 200 mg as two 100-mg capsules in the fed state

Subjects are randomized to receive 1 dose of investigational product (IP; belumosudil tablet or capsule) in the morning of Day 1 in a randomized manner following an overnight fast or a high-fat breakfast. Administration is performed on Day 1 with an appropriate interval between subjects based on logistical requirements. Start time is determined based on logistics.

Subjects undergo a screening visit in the 21 days preceding first dose. Subjects are admitted to the clinical unit on the evening prior to dosing (Day -1), remain on site until 24 hours post-dose, and return to the clinic at 36 and 48 hours post-dose for PK assessments.

There is a minimum washout period of 6 days between each dose administration. All other meals are standardized for each of the in-clinic phases of the 3 treatment periods. Each period follows the same study design.

The randomized cohorts for the 3-periods were as follows:

  • Cohort ABC: Regimen A (Period 1); Regimen B (Period 2); Regimen C (Period 3)
  • Cohort BCA: Regimen B (Period 1); Regimen C (Period 2); Regimen A (Period 3)
  • Cohort CAB: Regimen C (Period 1); Regimen A (Period 2); Regimen B (Period 3)

A follow-up call is made 3 to 5 days after the final dose of IP.

Planned enrollment is 24 subjects to insure there are 20 evaluable subjects. A subject is considered evaluable if (s)he completes treatment with fasted and fed tablet formulations (Regimens A and B) without major protocol deviations.

02

Conditions studied

  • Bioavailability
03

In context

Lead sponsor

Kadmon Corporation, LLC is the lead sponsor of 20 studies on the registry; none are open to participants now.

First submitted before Kadmon Corporation, LLC became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for study entry subjects has to satisfy all of the following criteria:

  1. Healthy males
  2. Aged 18 to 55 years of age
  3. Good state of health (mentally and physically) as indicated by a comprehensive clinical assessment (detailed medical history and a complete physical examination), , and laboratory investigations (hematology, coagulation, clinical chemistry and urinalysis)
  4. 18.0-30.0 kg/m\^2, or if outside the range, considered not by the Investigator
  5. Willing and able to communicate and participate in the whole study
  6. Provide written
  7. Agree to use an adequate method of for up to 90 days post discharge

Exclusion criteria

Exclusion Criteria

Subjects are excluded from the study if one of more of the following statements is applicable:

  1. Participated in a clinical research study within the previous 3 months
  2. Study site employees, or immediate family members of a study site or sponsor employee
  3. Had been previously enrolled in this study
  4. History of any drug or alcohol abuse in the past 2 years
  5. Regular alcohol consumption > 21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
  6. Current smokers and those who had smoked within the last 12 months. A breath carbon monoxide (CO) reading of greater than 10 ppm at screening
  7. Did not have suitable veins for multiple venepunctures/cannulation as assessed by the Investigator at screening
  8. abnormal biochemistry, hematology, coagulation, or urinalysis as judged by the Investigator
  9. Positive drugs of abuse test result or alcohol breath test
  10. Positive surface antigen (HBsAg), virus (HCV) antibody (Ab) or (HIV) results
  11. History of any clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal (GI) disease that may have compromised the subject's safety or interfered with the objectives of the study as judged by the investigator
  12. Subject had a history or presence of any of the following:

    • Active GI disease requiring therapy
    • Hepatic disease and/or (ALT) or aspartate aminotransaminase (AST) > 1.5 × (ULN) at screening
    • Renal disease and/or serum creatinine > 1.5 × ULN at screening
    • Other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
  13. corrected using Fridericia's formula (QTcF) > 450 msec at the screening or admission
  14. Serious adverse reaction or serious to any drug or the formulation
  15. Known sensitivity to ROCK2 inhibitor agents or to any of the constituents of the belumosudil formulation
  16. Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator. Hayfever is permitted unless it is active.
  17. Donation or loss of > 400 mL of blood within the previous 3 months
  18. Taking or had taken any prescribed or over-the-counter drug (other than 4 g per day paracetamol) or herbal remedies in the 14 days before IP administration
  19. Fails to satisfy the Investigator's discretion of fitness to participate or for any other reason

Additional Restrictions

  1. Abstain from alcohol during the 24 h prior to each admission until discharge from the clinic in each study period
  2. Not to drink liquids or eat food containing grapefruit, cranberry, caffeine, or other xanthines from 24 hours prior to each admission until 48 hours post-dose
  3. Refrain from eating food containing any seeds (e.g., poppy) for 48 hours before the screening visit and then from 48 h prior to each admission until discharge from the clinic for each study period
  4. Not to take part in any unaccustomed strenuous exercise from 72 hours prior to the screening visit and then from 72 hours prior to admission until discharge from the study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Regimen A

    Single-dose belumosudil 200 mg tablet in the fasted state

    Drug: Belumosudil Tablet

  • Experimental
    Regimen B

    Single-dose belumosudil 200 mg tablet in the fed state

    Drug: Belumosudil Tablet

  • Experimental
    Regimen C

    Single-dose belumosudil capsules (administered as two 100-mg capsules) in the fed state

    Drug: Belumosudil Capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Cmax of Dosing Regimen A (Tablets--Fasting) vs. Dosing Regimen B (Tablets--Fed) for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose

    Maximum concentration (Cmax) of parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) at 48 hours after dosing

    Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose

  2. Pharmacokinetics: AUCs of Dosing Regimen A (Tablets--Fasting) vs. Dosing Regimen B (Tablets--Fed) for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose

    Area under concentration-time curve from zero to last dose of belumosudil 200 mg tablets (AUC\[0-last\]) and from zero to infinity (AUC\[0-inf\]) for Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) at 48 hours after dosing

    Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose

Secondary outcomes

  1. Pharmacokinetics: Cmax for the Relative Bioavailability of Regimen B/Regimen A and Regimen B/Regimen C by Ratio of the Adjusted Geometric Means at 48 Hours Post-dose

    Analysis of the maximum concentration (Cmax) of the relative bioavailability of Regimen B (belumosudil 200 mg tablet-fed) vs. Regimen A (belumosudil 200 mg tablet-fasting) and for Regimen B vs. Regimen C (belumosudil 200 mg capsule-fed) utilizing the Ratio of the Adjusted Geometric Means at 48 hours after dosing

    Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose

  2. Pharmacokinetics: AUCs for the Relative Bioavailability of Regimen B/Regimen A and Regimen B/Regimen C by Ratio of the Adjusted Geometric Means at 48 Hours Post-dose

    Analysis of the area under concentration-time curve for zero to infinity (AUC\[0-inf\]), and zero to last dose (AUC\[0-last\]) of the relative bioavailability of Regimen B (belumosudil 200 mg tablet-fed) vs. Regimen A (belumosudil 200 mg tablet-fasting) and for Regimen B vs. Regimen C (belumosudil 200 mg capsule-fed) utilizing the Ratio of the Adjusted Geometric Means at 48 hours after dosing

    Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose

  3. Pharmacokinetics: Cmax of Dosing Regimen A (Tablets--Fasting) vs. Dosing Regimen B (Tablets--Fed) vs. Dosing Regimen C (Capsules--Fed) for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose

    Maximum concentration (Cmax) of parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) compared to a single dose of belumosudil 200 mg capsule (two 100-mg capsules) to subjects who are fed (Regimen C) at 48 hours after dosing

    Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose

  4. Pharmacokinetics: AUCs of Regimen A (Tablet--Fasting) vs. Dosing Regimen B (Tablet--Fed) vs. Dosing Regimen C (Capsule--Fed) for KD025, KD025m1, and KD025m2 for Belumosudil 200 mg at 48 Hours Post-dose

    Area under concentration curve from zero to last dose (AUC\[0-last\]) and from zero to infinity (AUC\[0-inf\]) for parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) compared to administering a single dose of 200 mg capsule (two 100-mg capsules) to subjects who are fed at 48 hours after dosing

    Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose

  5. Pharmacokinetics: Lambda-z for Regimens A, B, and C for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose

    Slope of the regression line passing through the apparent elimination phase in a concentration-time plot (Lambda-z) for Regimen A, Regimen B, and Regimen C for for the parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) at 48 hours after dosing

    Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose

  6. Pharmacokinetics: t(1/2), MRT(0-last), and MRT(0-inf) for Regimens A, B, and C for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose

    Apparent elimination half-life (t\[1/2\]), mean residence time from zero to last dose (MRT\[0-last\]), and MRT for zero to infinity (MRT\[0-inf\]) for Regimen A, Regimen B, and Regimen C for for the parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) at 48 hours after dosing

    Time frame: Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose

  7. Safety: Number of Subjects With TEAEs and SAEs

    Number of subjects with treatment-emergent adverse events (TEAEs), severity and relationship to belumosudil, serious adverse events (SAEs), TEAEs leading to withdrawal from study, and deaths. Treatment-emergent adverse events (TEAEs) are AEs that are not present before the first dose of IMP or that are present before the first dose of IMP but worsen in intensity during exposure to IMP. Severity: mild = 1; moderate = 2; severe = 3; life-threatening = 4; and death = 5. Related to belumosudil defined as possibly related, probably related, and related.

    Time frame: Approximately 1 month

  8. Safety: Total Number of Participants With TEAEs, Related TEAEs, Leading to Withdrawal, Severe, Serious, Leading to Death

    Total number of subjects who had treatment-emergent adverse events (TEAEs), TEAEs related to belumosudil, TEAEs leading to withdrawal of subject, severe TEAEs, serious TEAE (SAE), and TEAEs leading to death. Treatment-emergent adverse events (TEAEs) are AEs that are not present before the first dose of IMP or that are present before the first dose of IMP but worsen in intensity during exposure to IMP. Severity: mild = 1; moderate = 2; severe = 3; life-threatening = 4; and death = 5. Related to belumosudil defined as possibly related, probably related, and related.

    Time frame: Approximately 1 month

07

Results

Posted Oct 20, 2021

Participant flow

Enrollment: 23 subjects

Participant flow — Overall Study
MilestoneCohort ABCCohort BCACohort CAB
Started887
Completed685
Not completed202
Withdrew: Significant liver elevation101
Withdrew: Withdrawal by subject100
Withdrew: Illness of prohibited medication001

Outcome measures

PrimaryPharmacokinetics: Cmax of Dosing Regimen A (Tablets--Fasting) vs. Dosing Regimen B (Tablets--Fed) for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose

Maximum concentration (Cmax) of parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) at 48 hours after dosing

Time frame:
Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Cmax of Dosing Regimen A (Tablets--Fasting) vs. Dosing Regimen B (Tablets--Fed) for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose
ng/mLRegimen ARegimen B
Cmax: KD025821 ± 129.52100 ± 49.8
Cmax: KD025m119.4 ± 51.625.8 ± 42.0
Cmax: KD025m2173 ± 122.6412 ± 63.0
PrimaryPharmacokinetics: AUCs of Dosing Regimen A (Tablets--Fasting) vs. Dosing Regimen B (Tablets--Fed) for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose

Area under concentration-time curve from zero to last dose of belumosudil 200 mg tablets (AUC\[0-last\]) and from zero to infinity (AUC\[0-inf\]) for Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) at 48 hours after dosing

Time frame:
Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Geometric mean · (ng*h)/mL
Pharmacokinetics: AUCs of Dosing Regimen A (Tablets--Fasting) vs. Dosing Regimen B (Tablets--Fed) for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose
(ng*h)/mLRegimen ARegimen B
AUC(0-last): KD0254520 ± 121.39750 ± 49.3
AUC(0-last): KD025m119.8 ± 150.645.2 ± 95.3
AUC(0-last): KD025m2550 ± 133.31320 ± 62.6
AUC(0-inf): KD0254910 ± 146.910100 ± 52.9
AUC(0-inf): KD025m1153 ± 098.7 ± 0
AUC(0-inf): KD025m2691 ± 76.71370 ± 62.6
SecondaryPharmacokinetics: Cmax for the Relative Bioavailability of Regimen B/Regimen A and Regimen B/Regimen C by Ratio of the Adjusted Geometric Means at 48 Hours Post-dose

Analysis of the maximum concentration (Cmax) of the relative bioavailability of Regimen B (belumosudil 200 mg tablet-fed) vs. Regimen A (belumosudil 200 mg tablet-fasting) and for Regimen B vs. Regimen C (belumosudil 200 mg capsule-fed) utilizing the Ratio of the Adjusted Geometric Means at 48 hours after dosing

Time frame:
Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Number · Ratio of Adjusted Geometric Means
Pharmacokinetics: Cmax for the Relative Bioavailability of Regimen B/Regimen A and Regimen B/Regimen C by Ratio of the Adjusted Geometric Means at 48 Hours Post-dose
Ratio of Adjusted Geometric MeansRegimen B/Regimen ARegimen B/Regimen C
Pharmacokinetics: Cmax for the Relative Bioavailability of Regimen B/Regimen A and Regimen B/Regimen C by Ratio of the Adjusted Geometric Means at 48 Hours Post-dose225.02 (176.08 to 287.57)119.38 (93.41 to 152.56)
Statistical analysis
  • Regimen B/Regimen A · t-test, 2 sided · p = < 0.001 · Ratio of adjusted geometric means (%): 100 · 90% CI 80.00 to 125.00
  • Regimen B/Regimen C · t-test, 2 sided · p = 0.23 · Ratio of geometric means (%): 100 · 90% CI 80.00 to 125.00
SecondaryPharmacokinetics: AUCs for the Relative Bioavailability of Regimen B/Regimen A and Regimen B/Regimen C by Ratio of the Adjusted Geometric Means at 48 Hours Post-dose

Analysis of the area under concentration-time curve for zero to infinity (AUC\[0-inf\]), and zero to last dose (AUC\[0-last\]) of the relative bioavailability of Regimen B (belumosudil 200 mg tablet-fed) vs. Regimen A (belumosudil 200 mg tablet-fasting) and for Regimen B vs. Regimen C (belumosudil 200 mg capsule-fed) utilizing the Ratio of the Adjusted Geometric Means at 48 hours after dosing

Time frame:
Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Number · Ratio of Adjusted Geometric Means
Pharmacokinetics: AUCs for the Relative Bioavailability of Regimen B/Regimen A and Regimen B/Regimen C by Ratio of the Adjusted Geometric Means at 48 Hours Post-dose
Ratio of Adjusted Geometric MeansRegimen B/Regimen ARegimen B/Regimen C
AUC(0-inf)179.58 (143.16 to 225.26)118.43 (97.16 to 144.36)
AUC(0-last)187.92 (154.07 to 229.21)117.57 (96.40 to 143.40)
Statistical analysis
  • Regimen B/Regimen A · t-test, 2 sided · p = <0.001 · Ratio of adjusted geometric means (%): 100 · 90% CI 80.00 to 125.00
  • Regimen B/Regimen C · t-test, 2 sided · p = 0.16 · Ratio of adjusted geometric means (%): 100 · 90% CI 80.00 to 125.00
  • Regimen B/Regimen A · t-test, 2 sided · p = < 0.001 · Ratio of adjusted geometric means (%): 100 · 90% CI 80.00 to 125.00
  • Regimen B/Regimen C · t-test, 2 sided · p = 0.18 · Ratio of adjusted geometric means (%): 100 · 90% CI 80.00 to 125.00Intra-subject variability = 38.16%
SecondaryPharmacokinetics: Cmax of Dosing Regimen A (Tablets--Fasting) vs. Dosing Regimen B (Tablets--Fed) vs. Dosing Regimen C (Capsules--Fed) for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose

Maximum concentration (Cmax) of parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) compared to a single dose of belumosudil 200 mg capsule (two 100-mg capsules) to subjects who are fed (Regimen C) at 48 hours after dosing

Time frame:
Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Cmax of Dosing Regimen A (Tablets--Fasting) vs. Dosing Regimen B (Tablets--Fed) vs. Dosing Regimen C (Capsules--Fed) for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose
ng/mLRegimen ARegimen BRegimen C
Cmax: Parent Drug KD025821 ± 129.52100 ± 49.81750 ± 38.2
Cmax: KD025m119.4 ± 51.625.8 ± 42.020.6 ± 38.2
Cmax: KD025m2173 ± 122.6412 ± 63.0289 ± 76.5
SecondaryPharmacokinetics: AUCs of Regimen A (Tablet--Fasting) vs. Dosing Regimen B (Tablet--Fed) vs. Dosing Regimen C (Capsule--Fed) for KD025, KD025m1, and KD025m2 for Belumosudil 200 mg at 48 Hours Post-dose

Area under concentration curve from zero to last dose (AUC\[0-last\]) and from zero to infinity (AUC\[0-inf\]) for parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) when administering a single dose of belumosudil 200 mg tablet to subjects who are fasting (Regimen A) compared to administering a single dose of belumosudil 200 mg tablet to subjects who are fed (Regimen B) compared to administering a single dose of 200 mg capsule (two 100-mg capsules) to subjects who are fed at 48 hours after dosing

Time frame:
Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Geometric mean · (ng*h)/mL
Pharmacokinetics: AUCs of Regimen A (Tablet--Fasting) vs. Dosing Regimen B (Tablet--Fed) vs. Dosing Regimen C (Capsule--Fed) for KD025, KD025m1, and KD025m2 for Belumosudil 200 mg at 48 Hours Post-dose
(ng*h)/mLRegimen ARegimen BRegimen C
AUC(0-last): KD0254520 ± 121.39750 ± 49.38650 ± 42.7
AUC(0-last): KD025m119.8 ± 150.645.2 ± 95.333.6 ± 106.9
AUC(0-last): KD025m2550 ± 133.31320 ± 62.61000 ± 95.5
AUC(0-inf): KD0254910 ± 146.910100 ± 52.98710 ± 42.2
AUC(0-inf): KD025m1153 ± 098.7 ± 0213 ± 0
AUC(0-inf): KD025m2691 ± 76.71370 ± 62.61420 ± 47.7
SecondaryPharmacokinetics: Lambda-z for Regimens A, B, and C for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose

Slope of the regression line passing through the apparent elimination phase in a concentration-time plot (Lambda-z) for Regimen A, Regimen B, and Regimen C for for the parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) at 48 hours after dosing

Time frame:
Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Geometric mean · 1/hour
Pharmacokinetics: Lambda-z for Regimens A, B, and C for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose
1/hourRegimen ARegimen BRegimen C
KD0250.0622 ± 1.58480.0993 ± 1.52930.0967 ± 1.4594
KD025m10.3618 ± 00.3608 ± 00.1275 ± 0
KD025m20.4159 ± 1.52480.3291 ± 1.73260.2523 ± 1.7385
SecondaryPharmacokinetics: t(1/2), MRT(0-last), and MRT(0-inf) for Regimens A, B, and C for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose

Apparent elimination half-life (t\[1/2\]), mean residence time from zero to last dose (MRT\[0-last\]), and MRT for zero to infinity (MRT\[0-inf\]) for Regimen A, Regimen B, and Regimen C for for the parent drug (KD025), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) at 48 hours after dosing

Time frame:
Pre-dose (0), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Geometric mean · Hours
Pharmacokinetics: t(1/2), MRT(0-last), and MRT(0-inf) for Regimens A, B, and C for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose
HoursRegimen ARegimen BRegimen C
KD025: t(1/2)11.16 ± 1.586.98 ± 1.537.16 ± 1.46
KD025m1: t(1/2)1.92 ± 01.92 ± 05.44 ± 0
KD025m2: t(1/2)1.67 ± 1.522.11 ± 1.732.75 ± 1.74
KD025: MRT(0-last)7.25 ± 1.395.70 ± 1.276.21 ± 1.22
KD025m1: MRT(0-last)1.70 ± 1.612.45 ± 1.612.79 ± 1.57
KD025m2: MRT(0-last)3.03 ± 1.323.99 ± 1.454.44 ± 1.34
KD025: MRT(0-inf)9.35 ± 1.336.40 ± 1.277.18 ± 1.24
KD025m1: MRT(0-inf)3.38 ± 04.39 ± 08.26 ± 0
KD025m2: MRT(0-inf)3.46 ± 1.304.35 ± 1.464.86 ± 1.40
SecondarySafety: Number of Subjects With TEAEs and SAEs

Number of subjects with treatment-emergent adverse events (TEAEs), severity and relationship to belumosudil, serious adverse events (SAEs), TEAEs leading to withdrawal from study, and deaths. Treatment-emergent adverse events (TEAEs) are AEs that are not present before the first dose of IMP or that are present before the first dose of IMP but worsen in intensity during exposure to IMP. Severity: mild = 1; moderate = 2; severe = 3; life-threatening = 4; and death = 5. Related to belumosudil defined as possibly related, probably related, and related.

Time frame:
Approximately 1 month
Reported as:
Count of participants · Participants
Safety: Number of Subjects With TEAEs and SAEs
ParticipantsRegimen ARegimen BRegimen COverall
At least 1 TEAE6359
Reporting belumosudil-related TEAEs1001
TEAEs Leading to Withdrawal3003
Severe TEAEs1001
Serious TEAEs0000
TEAEs Leading to Death0000
SecondarySafety: Total Number of Participants With TEAEs, Related TEAEs, Leading to Withdrawal, Severe, Serious, Leading to Death

Total number of subjects who had treatment-emergent adverse events (TEAEs), TEAEs related to belumosudil, TEAEs leading to withdrawal of subject, severe TEAEs, serious TEAE (SAE), and TEAEs leading to death. Treatment-emergent adverse events (TEAEs) are AEs that are not present before the first dose of IMP or that are present before the first dose of IMP but worsen in intensity during exposure to IMP. Severity: mild = 1; moderate = 2; severe = 3; life-threatening = 4; and death = 5. Related to belumosudil defined as possibly related, probably related, and related.

Time frame:
Approximately 1 month
Reported as:
Count of participants · Participants
Safety: Total Number of Participants With TEAEs, Related TEAEs, Leading to Withdrawal, Severe, Serious, Leading to Death
ParticipantsRegimen ARegimen BRegimen COverall
All TEAEs73616
TEAEs Related to Belumosudil1001
TEAEs Leading to Withdrawal3003
Severe TEAEs1001
Serious TEAEs (SAE)0000
TEAEs Leading to Death0000

Adverse events

Collected over Approximately 1 month. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regimen A0/23 (0%)0/23 (0%)6/23 (26.1%)
Regimen B0/20 (0%)0/20 (0%)3/20 (15%)
Regimen C0/22 (0%)0/22 (0%)5/22 (22.7%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventRegimen ARegimen BRegimen C
HeadacheNervous system disorders0/231/201/22
NasopharyngitisInfections and infestations0/231/200/22
OropharyngealRespiratory, thoracic and mediastinal disorders0/231/200/22
ParesthesiaNervous system disorders0/230/201/22
SomnolenceNervous system disorders0/230/201/22
FatigueGeneral disorders0/230/201/22
Musculoskeletal painMusculoskeletal and connective tissue disorders0/230/201/22
Rash macularSkin and subcutaneous tissue disorders0/230/201/22
Cervical radiculopathyNervous system disorders1/230/200/22
Influenza-like illnessGeneral disorders1/230/200/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort ABCCohort BCACohort CABTotal
Mean34.1 ± 11.032.3 ± 12.443.0 ± 9.036.2 ± 11.5
Age, Continuous
Age, Continuous(Years)Cohort ABCCohort BCACohort CABTotal
Median32.5 (20 to 53)27.5 (21 to 50)46.0 (30 to 54)33.0 (20 to 54)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort ABCCohort BCACohort CABTotal
Female0000
Male88723
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort ABCCohort BCACohort CABTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1113
White77620
More than one race0000
Unknown or Not Reported0000
BMI (body mass index)
BMI (body mass index)(kg/m^2)Cohort ABCCohort BCACohort CABTotal
Mean26.19 ± 2.6725.79 ± 2.4326.53 ± 3.3526.15 ± 2.70
BMI (body mass index)
BMI (body mass index)(kg/m^2)Cohort ABCCohort BCACohort CABTotal
Median26.4 (22.4 to 29.3)26.0 (22.6 to 28.7)26.1 (22.1 to 30.0)26.10 (22.1 to 30.0)
08

Study locations

1 site
  • Quotient Clinical Limited
    Ruddington Nottingham, NG116JS, United Kingdom
09

References and documents

Publications

  • Schueller O, McDermott J, Evans P, Lohmer L, Alabanza A, Patel J. Phase 1 Studies to Evaluate the Food Effect and Relative Bioavailability of Tablet and Capsule Formulations of Belumosudil in Healthy Adult Subjects. Clin Pharmacol Drug Dev. 2022 Jul;11(7):807-814. doi: 10.1002/cpdd.1083. Epub 2022 Mar 2. PubMed 35238174 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2021, 6 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2015
First posted
Sep 23, 2015
Start
Sep 2015
Primary completionActual
Oct 12, 2015
CompletionActual
Oct 12, 2015
Results first posted
Oct 20, 2021
Last update
May 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02557139
Collaborators
Quotient Clinical
Responsible party
Sponsor
First posted
Sep 23, 2015
Start date
Sep 2015
Primary completion
Oct 12, 2015
Completion
Oct 12, 2015
Results posted
Oct 20, 2021
Last update
May 25, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion